

PROLIGHT SECURES FIRST TWO EUROPEAN PATENTS FOR PSYROS™ TECHNOLOGY

Prolight announces today that its first two European patents for the Psyros™ single molecule counting technology have been officially granted by the European Patent Office (EPO).

Both patents are being protected in 17 European jurisdictions, covering a population of around 540 million people. The first patent is valid until 2040 and the second until 2041. Protected territories include France, Germany, Italy, Poland, Spain, United Kingdom, Austria, Belgium, Ireland, the Netherlands, Portugal, Sweden, Switzerland, Turkey, Denmark, Finland, and Norway. An official communication will be published in the European Patent Bulletin on the 14th of May 2025.

“This milestone represents a major advancement for the Prolight intellectual property portfolio and enhances the attractiveness of our technology to potential partners,” said Ulf Bladin, CEO of Prolight.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight secures first two European patents for Psyros™ technology